Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation

Victor L. Serebruany, Seth D. Fortmann, Sunil V. Rao, Jean Francois Tanguay, Marie Lordkipanidze, Daniel F Hanley, Mehmet Can, Moo Hyun Kim, Thomas A. Marciniak

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Vorapaxar, a novel antiplatelet thrombin PAR-1 inhibitor, has been evaluated in the successful TRA2P trial and the failed TRACER trial. The drug is currently approved for post myocardial infarction and peripheral artery disease indications with concomitant use of clopidogrel and/or aspirin. The FDA ruled that the vorapaxar safety profile is acceptable. However, both trials revealed excess diplopia (double vision) usually reversible after vorapaxar. The diplopia risk appears to be small (about 1 extra case per 1,000 treated subjects), but real. Overall, there were 10 placebo and 34 vorapaxar diplopia cases (p=0.018) consistent for TRACER (2 vs 13 cases; p=0.010) and for TRA2P (8 vs 21 cases; p=0.018). Hence, we review the FDA-confirmed evidence and discuss potential causes and implications of such a surprising adverse association, which may be related to off-target PAR receptor mismodulation in the eye.

Original languageEnglish (US)
Pages (from-to)905-910
Number of pages6
JournalThrombosis and Haemostasis
Issue number5
StatePublished - May 1 2016


  • Adverse events
  • Clinical trials
  • Diplopia
  • PAR receptor
  • Safety
  • Vorapaxar

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation'. Together they form a unique fingerprint.

Cite this